MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism

Seok Ho Kim, Shin Hee Hong, Young Joon Park, Jong Hyuk Sung, Wonhee Suh, Kyeong Won Lee, Kiwon Jung, Changjin Lim, Jin Hee Kim, Hyoungsu Kim, Kyong Soo Park, Sang Gyu Park

Research output: Contribution to journalArticle

Abstract

Peroxisome proliferator-activated receptor (PPAR)-α/γ dual agonists have been developed to treat metabolic diseases; however, most of them exhibit side effects such as body weight gain and oedema. Therefore, we developed a novel PPARα/γ dual agonist that modulates glucose and lipid metabolism without adverse effects. We synthesised novel compounds composed of coumarine and chalcone, determined their crystal structures, and then examined their binding affinity toward PPARα/γ. We investigated the expression of PPARα and PPARγ target genes by chemicals in HepG2, differentiated 3T3-L1, and C2C12 cells. We examined the effect of chemicals on glucose and lipid metabolism in db/db mice. Only MD001 functions as a PPARα/γ dual agonist in vitro. MD001 increased the transcriptional activity of PPARα and PPARγ, resulting in enhanced expression of genes related to β-oxidation and fatty acid and glucose uptake. MD001 significantly improved blood metabolic parameters, including triglycerides, free fatty acids, and glucose, in db/db mice. In addition, MD001 ameliorated hepatic steatosis by stimulating β-oxidation in vitro and in vivo. Our results demonstrated the beneficial effects of the novel compound MD001 on glucose and lipid metabolism as a PPARα/γ dual agonist. Consequently, MD001 may show potential as a novel drug candidate for the treatment of metabolic disorders.

Original languageEnglish
Article number1656
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Peroxisome Proliferator-Activated Receptors
Lipid Metabolism
Glucose
3T3-L1 Cells
Chalcone
Coumarins
Metabolic Diseases
Nonesterified Fatty Acids
Weight Gain
Edema
Triglycerides
Fatty Acids
Body Weight
Gene Expression
Liver

All Science Journal Classification (ASJC) codes

  • General

Cite this

Kim, Seok Ho ; Hong, Shin Hee ; Park, Young Joon ; Sung, Jong Hyuk ; Suh, Wonhee ; Lee, Kyeong Won ; Jung, Kiwon ; Lim, Changjin ; Kim, Jin Hee ; Kim, Hyoungsu ; Park, Kyong Soo ; Park, Sang Gyu. / MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{1bbbe8ba4cef4293bf11945f625160a6,
title = "MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism",
abstract = "Peroxisome proliferator-activated receptor (PPAR)-α/γ dual agonists have been developed to treat metabolic diseases; however, most of them exhibit side effects such as body weight gain and oedema. Therefore, we developed a novel PPARα/γ dual agonist that modulates glucose and lipid metabolism without adverse effects. We synthesised novel compounds composed of coumarine and chalcone, determined their crystal structures, and then examined their binding affinity toward PPARα/γ. We investigated the expression of PPARα and PPARγ target genes by chemicals in HepG2, differentiated 3T3-L1, and C2C12 cells. We examined the effect of chemicals on glucose and lipid metabolism in db/db mice. Only MD001 functions as a PPARα/γ dual agonist in vitro. MD001 increased the transcriptional activity of PPARα and PPARγ, resulting in enhanced expression of genes related to β-oxidation and fatty acid and glucose uptake. MD001 significantly improved blood metabolic parameters, including triglycerides, free fatty acids, and glucose, in db/db mice. In addition, MD001 ameliorated hepatic steatosis by stimulating β-oxidation in vitro and in vivo. Our results demonstrated the beneficial effects of the novel compound MD001 on glucose and lipid metabolism as a PPARα/γ dual agonist. Consequently, MD001 may show potential as a novel drug candidate for the treatment of metabolic disorders.",
author = "Kim, {Seok Ho} and Hong, {Shin Hee} and Park, {Young Joon} and Sung, {Jong Hyuk} and Wonhee Suh and Lee, {Kyeong Won} and Kiwon Jung and Changjin Lim and Kim, {Jin Hee} and Hyoungsu Kim and Park, {Kyong Soo} and Park, {Sang Gyu}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-018-38281-0",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Kim, SH, Hong, SH, Park, YJ, Sung, JH, Suh, W, Lee, KW, Jung, K, Lim, C, Kim, JH, Kim, H, Park, KS & Park, SG 2019, 'MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism', Scientific Reports, vol. 9, no. 1, 1656. https://doi.org/10.1038/s41598-018-38281-0

MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism. / Kim, Seok Ho; Hong, Shin Hee; Park, Young Joon; Sung, Jong Hyuk; Suh, Wonhee; Lee, Kyeong Won; Jung, Kiwon; Lim, Changjin; Kim, Jin Hee; Kim, Hyoungsu; Park, Kyong Soo; Park, Sang Gyu.

In: Scientific Reports, Vol. 9, No. 1, 1656, 01.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism

AU - Kim, Seok Ho

AU - Hong, Shin Hee

AU - Park, Young Joon

AU - Sung, Jong Hyuk

AU - Suh, Wonhee

AU - Lee, Kyeong Won

AU - Jung, Kiwon

AU - Lim, Changjin

AU - Kim, Jin Hee

AU - Kim, Hyoungsu

AU - Park, Kyong Soo

AU - Park, Sang Gyu

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Peroxisome proliferator-activated receptor (PPAR)-α/γ dual agonists have been developed to treat metabolic diseases; however, most of them exhibit side effects such as body weight gain and oedema. Therefore, we developed a novel PPARα/γ dual agonist that modulates glucose and lipid metabolism without adverse effects. We synthesised novel compounds composed of coumarine and chalcone, determined their crystal structures, and then examined their binding affinity toward PPARα/γ. We investigated the expression of PPARα and PPARγ target genes by chemicals in HepG2, differentiated 3T3-L1, and C2C12 cells. We examined the effect of chemicals on glucose and lipid metabolism in db/db mice. Only MD001 functions as a PPARα/γ dual agonist in vitro. MD001 increased the transcriptional activity of PPARα and PPARγ, resulting in enhanced expression of genes related to β-oxidation and fatty acid and glucose uptake. MD001 significantly improved blood metabolic parameters, including triglycerides, free fatty acids, and glucose, in db/db mice. In addition, MD001 ameliorated hepatic steatosis by stimulating β-oxidation in vitro and in vivo. Our results demonstrated the beneficial effects of the novel compound MD001 on glucose and lipid metabolism as a PPARα/γ dual agonist. Consequently, MD001 may show potential as a novel drug candidate for the treatment of metabolic disorders.

AB - Peroxisome proliferator-activated receptor (PPAR)-α/γ dual agonists have been developed to treat metabolic diseases; however, most of them exhibit side effects such as body weight gain and oedema. Therefore, we developed a novel PPARα/γ dual agonist that modulates glucose and lipid metabolism without adverse effects. We synthesised novel compounds composed of coumarine and chalcone, determined their crystal structures, and then examined their binding affinity toward PPARα/γ. We investigated the expression of PPARα and PPARγ target genes by chemicals in HepG2, differentiated 3T3-L1, and C2C12 cells. We examined the effect of chemicals on glucose and lipid metabolism in db/db mice. Only MD001 functions as a PPARα/γ dual agonist in vitro. MD001 increased the transcriptional activity of PPARα and PPARγ, resulting in enhanced expression of genes related to β-oxidation and fatty acid and glucose uptake. MD001 significantly improved blood metabolic parameters, including triglycerides, free fatty acids, and glucose, in db/db mice. In addition, MD001 ameliorated hepatic steatosis by stimulating β-oxidation in vitro and in vivo. Our results demonstrated the beneficial effects of the novel compound MD001 on glucose and lipid metabolism as a PPARα/γ dual agonist. Consequently, MD001 may show potential as a novel drug candidate for the treatment of metabolic disorders.

UR - http://www.scopus.com/inward/record.url?scp=85061235733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061235733&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-38281-0

DO - 10.1038/s41598-018-38281-0

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 1656

ER -